Here's a roundup of top developments in the biotech space over the last 24 hours:
(Biotech Stocks Hitting 52-week Highs Nov. 2)
(Biotech Stocks Hitting 52-week Lows Nov. 2)
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) said topline results from its Phase 2/3 AUDREY clinical study evaluating voclosporin ophthalmic solution for the potential treatment of dry eye syndrome revealed the study did not meet its primary endpoint.
The primary endpoint was a 10mm or greater improvement in Schirmer Tear Test at four weeks between active dose groups of VOS compared to vehicle.
Aurinia said it is suspending the development program for VOS based upon these results.
The stock was down 8.26% premarket at $14.22.
Karyopharm Therapeutics (NASDAQ:KPTI) announced positive topline results from the Phase 3 portion of the SEAL study evaluating single agent oral Xpovio versus matching placebo in patients with advanced unresectable dedifferentiated liposarcoma.
The SEAL study met its primary endpoint of a statistically significant increase in progression-free survival, with Xpovio reducing the risk of disease progression or death by approximately 30%.
Separately, the company reported higher third-quarter revenues that fell short of some analyst estimates. The loss per share was a penny wider than estimates.
The stock was up 6.76% at $15.48 premarket.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) said the FDA has accepted the NDA for vosoritide, an investigational, once daily injection analog of C-type natriuretic peptide for children with achondroplasia, the most common form of disproportionate short stature in humans.
This acceptance by the FDA marks the first marketing application accepted for a treatment for achondroplasia in the U.S., BioMarin said.
The PDUFA date has been set for Aug. 20, 2021.
Related Link: The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings
OraSure Technologies, Inc. (NASDAQ:OSUR) said its DNA Genotek subsidiary has received emergency use authorization from the FDA for the use of the ORAcollect RNA saliva collection device for the collection, stabilization and transport of saliva specimens suspected of containing SARS-CoV-2 RNA.
This is the second FDA EUA that DNA Genotek has received for its saliva collection devices.
The stock was trading 9.17% higher at $16.25 premarket Tuesday.
Bristol-Myers Squibb Reports Positive Phase 3 Readout In Psoriasis
Bristol-Myers Squibb Co (NYSE:BMY) announced positive results from POETYK PSO-1, the first pivotal Phase 3 trial evaluating deucravacitinib, a selective tyrosine kinase 2 inhibitor, for the treatment of patients with moderate to severe plaque psoriasis.
The POETYK PSO-1 study evaluated 6 mg of deucravacitinib once daily met both co-primary endpoints versus placebo, with more patients achieving Psoriasis Area and Severity Index 75, defined as at least a 75% improvement in PASI, and a static Physician's Global Assessment score of clear or almost clear after 16 weeks of treatment with deucravacitinib, the company said.
Bristol-Myers Squibb also noted that the trial met multiple key secondary endpoints, including showing deucravacitinib was superior to Otezla in the proportion of patients reaching a PASI 75 response and sPGA 0/1 at Week 16.
In premarket trading Tuesday, the stock was up 3.46% to $61.55.
Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) third-quarter revenues rose from $46.2 million to $65.3 million. The company reversed from a loss of 17 cents per share to a profit of 25 cents per share. The company raised its full year 2020 guidance.
In after-hours trading, the stock gained 7.71% to $30.59.
Pacific Biosciences of California Inc (NASDAQ:PACB) said its third-quarter revenues slipped from $21.9 million to $19.1 million. The loss per share narrowed from 19 cents to 14 cents.
The stock was down 10.94% at $11.80 premarket.
Inspire Medical Systems Inc (NYSE:INSP) said its third-quarter revenues jumped 72% year-over-year to $35.8 million. The loss per share widened from 34 cents to 39 cents. The company raised its full-year revenue and gross margin guidance.
The stock was trading 12.24% higher at $136.65 premarket Tuesday.
Related Link: A Pfizer Analyst's 3 Possible Coronavirus Vaccine Readout Scenarios
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.